<DOC>
	<DOCNO>NCT02249208</DOCNO>
	<brief_summary>The purpose study determine detection rate false negative rate sentinel lymph node ( SLN ) superparamagnetic iron oxide ( SPIO ) alone addition radioisotope compare standard method ( blue radioisotope ) neoadjuvant chemotherapy patient node-positive breast cancer convert node negative treatment ultrasound . A randomized controlled trial .</brief_summary>
	<brief_title>Sentinel Lymph Node Biopsy With Superparamagnetic Iron Oxide Breast Cancer Patients After Neoadjuvant Treatment .</brief_title>
	<detailed_description>Identification Sentinel node : - Arm 1 ( Tc+blue dye ) : Identification SLN use standard technique sub-areolar injection technetium-99m ( Tc-99m ) vital blue dye surgery . - Arm 2 ( Tc+SPIO ) : Identification SLN use standard isotope technique sub-areolar injection technetium-99m ( Tc-99m ) surgery magnetic technique sub-areolar injection SPIO ( Sienna+® ) surgery detection SentiMag® probe . ( Study ) - Arm 3 ( SPIO alone ) : Identification SLN use magnetic technique sub-areolar injection SPIO ( Sienna+® ) surgery detection SentiMag® probe . ( Study ) Sentinel node 's excision radioactive / blue / magnetic ( colored brown-brown ) , detection guide hand probe gamma radiation , colorimetric / SentiMag® paramagnetic probe . Lymph node radioactive , blue , magnetic palpable consider SLNs resect submit pathological analysis . The protocol require least 2 SLNs resect . In case completion axillary lymphadenectomy node dissection ( ALND ) perform SLN biopsy . All SLNs excise submit perform ALND . Characterization nodal status patient detection rate false negative rate SLN arm .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Histologically proven primary invasive breast cancer clinical stage T1 T3 , N1 N2 , M0 accord American Joint Committee Cancer ( AJCC ) Cancer Staging Manual , seventh edition Completed plan undergo neoadjuvant chemotherapy Prechemotherapy axillary nodal disease confirm fineneedle aspiration coreneedle biopsy The axilla clinically radiologically ( ultrasound ) negative ( ycN0 ) postchemotherapy surgery Removal least two SLNs Signed informed consent patient study entry T4 tumor , cN3 cM1 The axilla clinically radiologically ( ultrasound ) positive ( ycN1 ) postchemotherapy Intolerance hypersensitivity compound iron dextran superparamagnetic iron oxide vital blue dye radioactive product . Chronic iron overload Pacemaker metallic implantable device chest wall Failure submit medical study geographical , social psychological Patient deprive liberty guardianship Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Sentinel Lymph Node</keyword>
	<keyword>Neoadjuvant Chemotherapy</keyword>
	<keyword>Clinically Node-Positive biopsy-proven cN1</keyword>
	<keyword>False-negative Rate</keyword>
</DOC>